Plasma proteome analysis and validation of patients with community-acquired pneumonia

Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide. Timely diagnostic and prognostic assessment of CAP severity are crucial for early recognition and appropriate therapy in affected patients. However, the use of laboratory biomarkers for accurate and reliable prediction of CAP severity is still in debate. Through analysis of plasma proteomics, we have identified potential biomarkers associated with diagnosis and severity of CAP.